In August, KFF Health News reported that Medicare now pays US surgeons around $520 for a standard cataract operation, roughly 20% less than a decade ago, and that many are turning to more lucrative laser upgrades to compensate. US cataract surgeons have been saying publicly that this is unsustainable. They are, of course, completely right. Although the healthcare system in the UK differs, the underlying story is much the same. Below, I'll set out what has happened in the UK, because the headline number only tells part of the story.
Over the last 20 years, cataract surgery has become one of the great health success stories of modern medicine. It’s quicker than it used to be and is now also significantly safer. It’s also more precise in the outcomes it can achieve. Patients that once faced a significant operation with a guarded prognosis can now expect a short procedure and an excellent outcome. What often goes unspoken is that, over the same period, the cost of delivering cataract surgery to modern standards rose, while the amount paid to perform it fell. This wasn't a one-off reduction, but a steady decline over time.
Improvements in cataract surgery include advances in phacoemulsification techniques and more accurate biometry. Intraocular lens design has also progressed from simple monofocal optics to toric, extended depth of focus, and trifocal lenses. Better surgical training, coupled with higher case volumes, has also helped to drive complication rates down. All of this contributes to genuine benefit for patients.
However, such progress doesn't come without costs: modern biometers and imaging platforms are expensive to purchase and maintain, and many consumables are now single-use. These single-use items – as well as the sterilization processes used for reusable instruments – both carry financial and environmental costs. A contemporary single cataract operation generates significant quantities of waste, and the equipment and infrastructure now needed to deliver surgery safely are more expensive than they used to be.
Another cost – perhaps unspoken and less visible to patients – is the time involved in the process surrounding surgery. Whether it is obtaining consent, counseling patients, documenting everything involved, or post-operative patient communication, all of this takes up a significant amount of a surgeon's day. These factors are understandably driven by higher expectations and a medicolegal climate in which every step needs to be properly recorded and defensible. Safer, better surgery is therefore more expensive to provide.
Despite these rising surgical costs, it has become increasingly apparent that payment for the surgeon has moved steadily in the opposite direction. The surgeon's fee paid by UK insurers for cataract surgery has fallen from around £850 per eye when I began my career in ophthalmology in 2003 to roughly £255-£300 per eye today. That’s a fall of approximately two-thirds, before any adjustments are made for more than 20 years of inflation. In real terms, the decline is even steeper still.
The fees insurers pay are not routinely made public. The figures above are based on what I see firsthand; they are surgeon's fees only and exclude any additional hospital charges. The challenge, though, is not simply funding an uncomplicated operation; it is funding the responsibility that remains when recovery is prolonged or further treatment is needed.
Advances in techniques and technology have made cataract surgery faster, safer, and more predictable, but it appears that these improvements may have been used to justify lower reimbursement – perhaps based on an assumption that a more routine procedure costs less?
As a result of these improvements, in my view cataract surgery has also become more demanding. Patients expect more, paperwork has increased, and even rare complications attract greater medicolegal scrutiny. This could partly explain why some ophthalmologists are choosing to step away from routine cataract work and/or focus on better-paid cases. As individual surgeons, we have very little power to reverse these systemic changes. But what we can control is how we respond to the added pressures these changes generate.
At Blue Fin Vision, the eye care clinic I founded in London in 2022, we decided not to compete on price. We could have tried to do more operations for less money, but that would have risked leaving less time for each patient. Instead, we've built a premium service around more tailored, personalized care. We invest in advanced diagnostics and technology and offer a wide range of treatment options. We also make sure there's sufficient time to discuss those options properly. We counsel our patients before surgery and support them throughout their recovery. That's how we've adapted our business model without compromising on our clinical standards.
By “premium,” we don't mean that patients who pay more receive a better standard of clinical care. We mean that patients are able to choose additional options, such as premium intraocular lenses or intravenous sedation. However, these options don't buy a safer operation or a more careful surgeon – whether a patient chooses a standard monofocal lens or a premium lens, they see the exact same surgeon and receive the exact same consultation time, and they are supported by the same team throughout their recovery. What changes is the choice of treatments and services available, not the standard of care.
As cataract surgery has evolved, patient expectations have also changed. Twenty years ago, patients primarily wanted their cataract removed safely and efficiently. Now, many patients expect perfect vision without glasses, glare, haloes, or any accompanying dry eye. They also want to be back at work, driving – even flying! – almost immediately.
We know that even when surgery goes well, this rapid recovery time isn't always possible. Some patients can experience temporary corneal swelling, glare, or haloes, while others will need time to adjust to their new lens. Even with careful measurements, the final visual result may differ slightly from what was originally expected. These are known aspects of a normal recovery and they don't necessarily mean anything has gone wrong.
Another growing concern in the cataract space is the growing use of AI to summarize patient reviews. Rather than reading individual accounts, patients can sometimes rely on such AI-derived summaries to choose their surgeon. The problem with this sort of outsourced decision-making process is that important details can get lost. For example, a human-led review might praise a surgeon but mention that it took several weeks to adjust to a new lens. For that exact same scenario, an AI summary might leave out that key detail, focusing instead solely on the positive experience of the patient.
My concern is that this type of AI-truncated review can also give patients unrealistic expectations about surgery and recovery time. It creates a problem for surgeons who want to be honest and transparent with patients about recovery. Explaining that someone could experience haloes or glare for a few weeks might sound less reassuring, but patients need to understand what recovery from a surgical operation, however routine, may involve.
Our approach at Blue Fin Vision gives us more time to manage expectations. We explain what recovery may involve, including elements like neuroadaptation. Plus, we share clinical outcome data and we never promise perfect results, supporting patients throughout their recovery, particularly when they need reassurance.
This brings me to the cost that rarely features in discussions about reimbursement: the cost involved when something goes wrong. Even in experienced hands, a small proportion of operations will be complicated by posterior capsule rupture, a dropped nucleus, or a later retinal detachment. Every patient choosing private surgery should be able to ask before they book: If I need another operation, who will perform it, where will it happen, how quickly can it be arranged, and who pays? They should also know whether a complication would be managed within their private care or require referral elsewhere, including to the NHS, and what that would mean for continuity, timing, and overall cost.
Answering those questions properly also has a cost, and it is increasingly difficult to fund from a falling fee. A surgeon's fee of £255 - £300 per eye has to support more than the operation itself. When a complication arises, urgent review, extended follow-up, arranging vitreoretinal surgery, and remaining available throughout can create substantial additional work, much of which attracts no separate payment. Owning that work, rather than passing it on, has to be funded from somewhere.
At Blue Fin Vision, we fund it through our pricing. We invested around £50,000 in our own vitreoretinal capability; further surgery is performed privately by a named consultant vitreoretinal surgeon, with emergency retinal cover seven days a week; and the cost of managing a complication is covered on terms we explain before surgery. That is a large part of why we chose the premium space rather than depend on insurer reimbursement.
Cataract surgery is better and safer than it has ever been, yet, in my experience, surgeons are paid far less for it than they were 20 years ago. Each practice will respond in its own way. Whatever the model, the price of surgery has to account for the operation that does not go to plan, and patients should know before they book who will carry that responsibility.
Insurers may continue to pay less for a better, safer operation. But the surgeon’s responsibility for the patient does not also shrink with that fee.
